In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of GlaxoSmithKline plc (NYSE:GSK), nVent Electric PLC (NYSE:NVT), Dana Incorporated (NYSE:DAN), FMC Corporation (NYSE:FMC), Qualys, Inc. (NASDAQ:QLYS), and Affiliated Managers Group, Inc. (NYSE:AMG), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

GSK DOWNLOAD: http://Capital-Review.com/register/?so=GSK NVT DOWNLOAD: http://Capital-Review.com/register/?so=NVT DAN DOWNLOAD: http://Capital-Review.com/register/?so=DAN FMC DOWNLOAD: http://Capital-Review.com/register/?so=FMC QLYS DOWNLOAD: http://Capital-Review.com/register/?so=QLYS AMG DOWNLOAD: http://Capital-Review.com/register/?so=AMG

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine GlaxoSmithKline plc (NYSE:GSK), nVent Electric PLC (NYSE:NVT), Dana Incorporated (NYSE:DAN), FMC Corporation (NYSE:FMC), Qualys, Inc. (NASDAQ:QLYS), and Affiliated Managers Group, Inc. (NYSE:AMG) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed February 28th, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

GLAXOSMITHKLINE PLC (GSK) REPORT OVERVIEW

GlaxoSmithKline plc's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, GlaxoSmithKline plc reported revenue of $10,543.88MM vs $10,268.06MM (up 2.69%) and analysts estimated basic earnings per share $0.75 vs $0.65 (up 15.65%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, GlaxoSmithKline plc reported revenue of $41,139.87MM vs $38,903.72MM (up 5.75%) and analysts estimated basic earnings per share $1.97 vs $0.81 (up 143.49%). Analysts expect earnings to be released on April 24th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.68. The estimated EPS forecast for the next fiscal year is $3.03 and is expected to report on February 5th, 2020.

To read the full GlaxoSmithKline plc (GSK) report, download it here: http://Capital-Review.com/register/?so=GSK

-----------------------------------------

NVENT ELECTRIC PLC (NVT) REPORT OVERVIEW

nVent Electric's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, nVent Electric reported revenue of $568.10MM vs $541.90MM (up 4.83%) and analysts estimated basic earnings per share $0.38 vs $0.87 (down 56.32%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, nVent Electric reported revenue of $2,213.60MM vs $2,097.90MM (up 5.52%) and analysts estimated basic earnings per share $1.29 vs $2.02 (down 36.14%). Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. The estimated EPS forecast for the next fiscal year is $2.05 and is expected to report on January 30th, 2020.

To read the full nVent Electric PLC (NVT) report, download it here: http://Capital-Review.com/register/?so=NVT

-----------------------------------------

DANA INCORPORATED (DAN) REPORT OVERVIEW

Dana's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Dana reported revenue of $1,973.00MM vs $1,837.00MM (up 7.40%) and analysts estimated basic earnings per share $0.69 vs -$0.75. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Dana reported revenue of $8,143.00MM vs $7,209.00MM (up 12.96%) and analysts estimated basic earnings per share $2.94 vs $0.72 (up 308.33%). Analysts expect earnings to be released on April 29th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.75. The estimated EPS forecast for the next fiscal year is $3.54 and is expected to report on February 21st, 2020.

To read the full Dana Incorporated (DAN) report, download it here: http://Capital-Review.com/register/?so=DAN

-----------------------------------------

FMC CORPORATION (FMC) REPORT OVERVIEW

FMC's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, FMC reported revenue of $1,219.20MM vs $979.60MM (up 24.46%) and basic earnings per share $0.24 vs $3.95 (down 93.92%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, FMC reported revenue of $4,727.80MM vs $2,878.60MM (up 64.24%) and analysts estimated basic earnings per share $3.72 vs $3.99 (down 6.77%). Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $1.84. The estimated EPS forecast for the next fiscal year is $6.55 and is expected to report on February 10th, 2020.

To read the full FMC Corporation (FMC) report, download it here: http://Capital-Review.com/register/?so=FMC

-----------------------------------------

QUALYS, INC. (QLYS) REPORT OVERVIEW

Qualys' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Qualys reported revenue of $74.20MM vs $62.92MM (up 17.94%) and analysts estimated basic earnings per share $0.37 vs $0.07 (up 428.57%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Qualys reported revenue of $278.89MM vs $230.83MM (up 20.82%) and analysts estimated basic earnings per share $1.47 vs $1.08 (up 36.11%). Analysts expect earnings to be released on May 7th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.22. The estimated EPS forecast for the next fiscal year is $1.43 and is expected to report on February 11th, 2020.

To read the full Qualys, Inc. (QLYS) report, download it here: http://Capital-Review.com/register/?so=QLYS

-----------------------------------------

AFFILIATED MANAGERS GROUP, INC. (AMG) REPORT OVERVIEW

Affiliated Managers Group's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Affiliated Managers Group reported revenue of $564.40MM vs $604.10MM (down 6.57%) and analysts estimated basic earnings per share -$2.88 vs $5.65. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Affiliated Managers Group reported revenue of $2,378.40MM vs $2,305.00MM (up 3.18%) and analysts estimated basic earnings per share $4.55 vs $12.30 (down 63.01%). Analysts expect earnings to be released on April 29th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $3.92. The estimated EPS forecast for the next fiscal year is $15.31 and is expected to report on February 3rd, 2020.

To read the full Affiliated Managers Group, Inc. (AMG) report, download it here: http://Capital-Review.com/register/?so=AMG

-----------------------------------------

ABOUT CAPITAL REVIEW

Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.

REGISTERED MEMBER STATUS

Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact: Nicole Garrens, Media Department Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com

© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more GSK Charts.